Functional food composition for the relief of irritable bowel syndrome - Patent Application 20070122999

Abstract

The present invention relates to a functional food composition for alleviating irritable bowel syndrome (IBS), comprising an extract of Cymbidium sieboldii as an active ingredient. More specifically, the extract of Cymbidium sieboldii is effective in alleviating IBS by improving diarrhea and / or borborygmus symptoms.

Description

[Technical Field]

[0001] This application claims the benefit of priority based on Korean Patent Application No. 10-2019-0103194, filed on August 22, 2019, and all contents disclosed in the documents of said Korean patent application are incorporated herein by reference.

[0002] The present invention relates to a functional food composition for alleviating irritable bowel syndrome, which contains an extract of Lonicera japonice as an active ingredient. [Background technology]

[0003] Irritable bowel syndrome (IBS) is a chronic functional disorder characterized by lower abdominal bloating, discomfort, abdominal pain, frequent bowel movements, diarrhea or constipation, or alternations between these, flatulence, and unpleasant odors. It is characterized by nonspecific and diverse clinical symptoms, without any anatomical or temperamental abnormalities.

[0004] Although the definition of irritable bowel syndrome varies slightly depending on the researcher, the Rome Criteria II, which reflects the most recent research findings on functional gastrointestinal disorders, defines it as a group that includes various functional bowel disorders in which abdominal discomfort or pain is related to defecation, or is accompanied by changes in bowel habits or abnormal defecation characteristics. According to data reported by Manning et al. in 1978, four symptoms were statistically significantly more common in patients with irritable bowel syndrome: abdominal pain relieved by stool, loose stools at the time of symptoms, increased bowel frequency at the time of pain, and abdominal bloating; two symptoms, mucus in the stool and a feeling of incomplete evacuation, also tended to be more common in patients with irritable bowel syndrome.

[0005] In 1989, a group of international experts came together to diagnose IBS symptoms and came up with the Roman Criteria I for various functional gastrointestinal disorders. IBS was diagnosed when abdominal pain or discomfort accompanied by changes in bowel frequency or stool form persisted for more than three months and was accompanied by two or more of the following five bowel disorders: (1) changes in bowel frequency, (2) changes in stool form, (3) abnormal bowel evacuation, (4) mucus in the stool, and (5) abdominal distension. These diagnostic criteria were revised and supplemented over the years, becoming Roman Criteria II in 1999 and Roman Criteria III in 2006. Currently, Roman Criteria II is the most widely used criterion, and its diagnosis is based on symptoms beginning at least six months prior to the onset of symptoms, and abdominal pain or discomfort relieved by bowel movements for at least three days each month for the past three months, or changes in frequency or form. It is also classified into subtypes of irritable bowel syndrome, namely diarrhea type, constipation type, and alternating diarrhea and constipation type.

[0006] Although the exact cause of IBS is unknown, it is generally believed to be due to a combination of factors, including altered intestinal motility, visceral hypersensitivity, psychosocial factors, neurotransmitter imbalance, bacterial infection, or inflammation. While the exact mechanism of IBS remains unclear, recent studies have revealed a relationship with serotonin levels, a neurotransmitter. In particular, blood serotonin levels are known to be primarily influenced by intestinal serotonin levels, which affect diarrhea-predominant IBS. Other potential mechanisms include visceral stimulation originating from the gastrointestinal wall, altered interactions between the mucosal immune system and afferent nerve endings in the intestine due to low-grade inflammation, and oxidative stress.

[0007] In particular, oxidative stress that causes DNA damage has been reported to increase ulcers in the intestinal mucosa, and the biomarker most commonly used in this case is 8-OHdG (8-hydroxy-2'-deoxyguanosine). Intestinal mucosal damage has been reported to affect diarrhea-predominant symptoms of irritable bowel syndrome.

[0008] Since the main causes of irritable bowel syndrome are weak intestines or stress, it is expected that treating only symptoms such as constipation or diarrhea will not have a fundamental effect, but relieving stress will have a fundamental effect. In addition, in order to develop foods or therapeutic agents that can achieve such effects, active research is being conducted to obtain active ingredients from natural products that have few or no side effects, but no significant results have been reported so far.

[0009] In recent years, research results have been published on the anti-inflammatory, antibacterial, antipyretic, hepatoprotective, anticancer, immune, anti-allergic, lipid metabolism, anti-arthritic, and sedative effects of rhododendron extract, among other natural products, raising interest in its use in food and medicine.

[0010] Honeysuckle (Lonicera japonica Thunberg), a member of the caprifoliaceae family, is a dried bud or flower that has just begun to bloom. All parts of honeysuckle, including the stem, leaves, roots, and flowers, have long been used as traditional Chinese medicine. It is recorded in the Chinese Pharmacopoeia as a drug used for thousands of years in Traditional Chinese Medicine (TCM). It is known in China for its superior efficacy to ginseng. Honeysuckle flowers have a pleasant fragrance, a honey-like aroma, and a mild, slightly bitter taste. Honeysuckle has traditionally been used for headaches, acute fevers, sore throats, and infections. Recent research has shown that it has anti-inflammatory, antibacterial, antipyretic, hepatoprotective, anti-cancer, immune, anti-allergic, lipid metabolism, anti-arthritis, and sedative effects.

[0011] Patent Document 1 relates to a food composition using a rhododendron extract for treating or preventing gastrointestinal motility disorders. Specifically, it discloses that the acetate fraction of the rhododendron aqueous extract is effective in improving one or more of the following gastrointestinal motility disorder symptoms: functional dyspepsia, constipation, irritable bowel symptoms, diabetic gastrointestinal motility disorder, gastrointestinal motility disorder caused by chemotherapy, intestinal atresia caused by gastrointestinal motility disorder, and gastrointestinal motility disorder caused by myotonic dystrophy. While the patent suggests the use of rhododendron extract for improving gastrointestinal motility disorders, it only mentions symptoms related to gastrointestinal motility and does not propose a solution for improving various gastrointestinal symptoms.

[0012] Thus, although research into foods or drugs related to Cymbopogon extract for improving various gastrointestinal-related symptoms is ongoing, no specific research has been conducted into foods or drugs related to improving irritable bowel syndrome accompanied by diarrhea. [Prior art documents] [Patent documents]

[0013] [Patent Document 1] Korean Patent No. 1605312 Summary of the Invention [Problem to be solved by the invention]

[0014] Therefore, an object of the present invention is to provide a functional food composition for alleviating irritable bowel syndrome, which contains an extract of Goldenrod as an active ingredient.

[0015] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating irritable bowel syndrome, which contains an extract of Cymbidium sieboldii as an active ingredient. [Means for solving the problem]

[0016] To achieve the above object, the present invention provides a functional food composition for alleviating irritable bowel syndrome, which comprises an extract of Cymbidium sieboldii as an active ingredient.

[0017] The present invention also provides a pharmaceutical composition for alleviating irritable bowel syndrome, comprising an extract of Cymbidium chinense as an active ingredient. [Effects of the Invention]

[0018] According to the present invention, the extract of Cymbopogon sieboldii improves diarrhea and alleviates the symptoms of irritable bowel syndrome (IBS). Specifically, the extract of Cymbopogon sieboldii improves increased passage of stools, loose stools, and urgent need for defecation, thereby alleviating IBS.

[0019] Furthermore, the extract of the present invention improves borborygmus, which is one of the symptoms associated with irritable bowel syndrome, and is effective in alleviating irritable bowel syndrome.

[0020] In addition, the extract of the Golden Ginseng flower reduces the blood concentration of 8-OHdG (8-hydroxy-2'-deoxyguanosine), which is used as a biological indicator of oxidative stress, and has the effect of alleviating irritable bowel syndrome.

[0021] Furthermore, among the above-mentioned extracts of Goldenrod, the aqueous extract of Goldenrod may be more effective in alleviating irritable bowel syndrome accompanied by borborygmus and / or diarrhea. [Brief explanation of the drawings]

[0022] [Figure 1] 1 is a graph showing the results of evaluating the degree of improvement in constipation and diarrhea symptoms in a test group administered with the rhododendron extract of Example 1 and a control group. [Figure 2] 1 is a graph showing the results of evaluating the degree of improvement in minor symptoms related to constipation and diarrhea in a test group administered with the rhododendron extract of Example 1 and a control group. [Figure 3] 1 is a graph showing the results of evaluating the degree of improvement in borborygmus symptoms for a test group administered with the rhododendron extract of Example 1 and a control group. [Figure 4] 1 is a graph showing the results of hematological analysis related to blood 8-OHdG concentration for the test group administered with the rhododendron extract of Example 1 and the control group. DETAILED DESCRIPTION OF THE INVENTION

[0023] The present invention will be described in more detail below.

[0024] Food composition The present invention relates to a functional food composition for alleviating irritable bowel syndrome, which contains an extract of Cymbidium ginseng as an active ingredient.

[0025] Honeysuckle is the flower of the honeysuckle (Lonicera japonica Thunberg) plant, which belongs to the Caprifoliaceae family. It is also called honeysuckle, honeysuckle grass, or honeysuckle flower.

[0026] The gold leaf extract may be extracted with a solvent selected from water, alcohol having 1 to 4 carbon atoms, or a mixture thereof.

[0027] The sweet laurel extract may be an organic solvent fraction of the sweet laurel extract, which refers to a substance obtained by systematically fractionating the sweet laurel extract using one or more of the following organic solvents, either individually or sequentially:

[0028] The organic solvent may include one or more selected from the group consisting of hexane, ethyl acetate, dichloromethane, chloroform, and butanol.

[0029] For example, the organic solvent fraction of the rhododendron extract may be an ethyl acetate fraction of the rhododendron extract as described below, taking into consideration the efficacy of alleviating irritable bowel syndrome.

[0030] The extract of the rhododendron may be an extract of the rhododendron extracted using water, which may be effective in alleviating the symptoms of irritable bowel syndrome with diarrhea (disease code: K58.0), a type of irritable bowel syndrome.

[0031] According to the Gastrointestinal Symptom Rating Scale (GSRS), the diarrhea symptoms can include increased passage of stools, loose stools, and urgent need for defecation.

[0032] Therefore, the extract of Cyperus sieboldii can improve diarrhea symptoms such as increased bowel movements, loose stools and urgent bowel movements, and alleviate the symptoms of irritable bowel syndrome accompanied by diarrhea.

[0033] In addition, the rhododendron extract can improve borborygmus, a symptom associated with irritable bowel syndrome. Borborygmus is a sound generated in the stomach and intestinal tract. When food intake is low and gas is abundant, or when food is not digested, excessive gas is produced. When gas is generated, the stomach muscles contract, causing a rumbling sound as liquid and gas move forward. The rhododendron extract can improve borborygmus and alleviate irritable bowel syndrome.

[0034] The content of the rhododendron extract is not particularly limited, but may be 0.1 to 10 wt % based on the total weight of the food composition, taking into consideration the effect of alleviating symptoms associated with irritable bowel syndrome as described above.

[0035] In the present invention, the dosage form of the food composition is not particularly limited, and may be, for example, a tablet, capsule, powder, liquid phase, granule, ring, single phase, paste, syrup, gel, jelly, caramel, gummy, or bar form.

[0036] The food composition of the present invention may further contain commonly used excipients and / or additives, such as binders, disintegrants, sweeteners, flavorings, colorings, or preservatives, but is not limited thereto as long as they are commonly acceptable additives for food compositions.

[0037] The excipient is not particularly limited in the present invention as long as it is a substance added to make the formulation easier to take or to form a certain shape, and examples of such excipients include, but are not limited to, maltodextrin, starch, calcium carbonate, sucrose, lactose, glucose, mannitol, isomalt, xylitol, gelatin, (micro)crystalline cellulose, sorbitol, maltitol, HPMC (hypromellose), sodium lauryl sulfate, sodium alginate, calcium phosphate, etc.

[0038] The binder is a substance that enables the formulation to maintain its form, and may be, for example, one or more selected from water, an aqueous suspension of a methacrylic acid copolymer, an aqueous suspension of ethyl cellulose, an aqueous suspension of polyvinyl acetate, and magnesium stearate.

[0039] The disintegrant is used to promote disintegration in the digestive tract, and may be, for example, one or more selected from hydroxypropylmethylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, sodium lauryl sulfate, anhydrous silicic acid, 1-hydroxypropylcellulose, dextran, starch, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, medium-strength polyvinylpyrrolidone, gum arabic, amylopectin, pectin, sodium polyphosphate, ethylcellulose, hexasaccharide, and magnesium aluminum silicate.

[0040] The sweetener serves to mask bitterness, and examples of the sweetener that can be used include sucrose, glucose, D-sorbitol, aspartame, licorice extract, erythritol, steviol glycoside, and enzyme-treated stevioside.

[0041] Examples of the fragrance that can be used include orange oil, fruit juice extract, cinnamon oil, spearmint oil, mint, vanilla, citrus mint oil, rose oil, lemon oil, berry scent, strawberry scent, grape scent, berry scent, and yogurt scent.

[0042] Examples of the coloring agent that can be used include artificial coloring agents such as synthetic food coloring agents, and natural coloring agents such as gardenia yellow, cochineal extract color, caramel color, monascus red color, and saffron color.

[0043] Examples of the preservative that can be used include dehydroacetic acids, sorbic acids, benzoic acids, propionic acids, and parahydroxybenzoic acid esters.

[0044] In addition, the food composition of the present invention may further contain commonly used additives such as stabilizers, thickeners, bulking agents, or pH adjusters.

[0045] The types of foods to which the rhododendron extract can be added are not particularly limited, and examples thereof include meat, sausage, bread, chocolate, candy, snacks, pizza, ramen, other noodles, dairy products including ice cream, various soups, drinking water, energy drinks, alcoholic drinks, and vitamin mixtures, including all health foods in the usual sense.

[0046] The spiracles extract according to the present invention can be produced by crushing spiracles, adding an extraction solvent, and heating.

[0047] The extraction can be carried out at a temperature of 50 to 100°C, preferably 60 to 95°C, for 1 to 10 hours, preferably 3 to 7 hours.

[0048] After obtaining the extract of Cyperus sieboldii, the extract may be further concentrated, and the concentration may be carried out at a temperature of 30 to 70°C for 1 to 10 hours.

[0049] In addition, an excipient can be added to powderize the concentrated diadem extract. Examples of the excipient include maltodextrin, starch, lactose, and crystalline cellulose. The diadem extract and the excipient can be mixed in a ratio of 10:90 to 50:50 to produce a powder. The extract after mixing with the excipient can be dried by vacuum drying, spray drying, or freeze drying, and the diadem extract is produced through these processes. The drying process can be carried out at a temperature of 20 to 100°C for 15 to 18 hours.

[0050] In this case, the extraction solvent may be selected from water, alcohols having 1 to 4 carbon atoms, and mixtures thereof. In consideration of the efficacy of alleviating the symptoms of irritable bowel syndrome, the extraction solvent may be water.

[0051] Alternatively, the concentrated spiracles extract may be suspended in water and then fractionated with an organic solvent to obtain an organic solvent fraction of the spiracles extract.

[0052] Pharmaceutical Composition The present invention relates to a pharmaceutical composition for alleviating irritable bowel syndrome, comprising an extract of Cymbidium sieboldii as an active ingredient, and specifically, the pharmaceutical composition may be a pharmaceutical composition for preventing or treating irritable bowel syndrome.

[0053] The irritable bowel syndrome may be borborygmi; and / or irritable bowel syndrome with diarrhea, and the irritable bowel syndrome with diarrhea may include one or more symptoms selected from the group consisting of increased bowel movements, loose stools, and bowel urgency.

[0054] In the present invention, the pharmaceutical composition may further include an excipient and / or additive, and the excipient and / or additive are not particularly limited as long as they are pharmaceutically acceptable.

[0055] For example, the excipient may be maltodextrin, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, or mineral oil.

[0056] The additive may be a carrier, diluent, filler, extender, binder, wetting agent, disintegrant, or surfactant that is commonly used to formulate a pharmaceutical composition.

[0057] In the present invention, the pharmaceutical composition containing the extract of Cymbidium sieboldii as an active ingredient can be formulated for oral or parenteral administration.

[0058] The dosage form for oral administration may be, for example, one or more selected from the group consisting of tablets, pills, hard / soft capsules, liquids, suspensions, emulsions, syrups, and granules.

[0059] The parenteral dosage form may be one or more selected from the group consisting of a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized preparation, and a suppository. The parenteral dosage form may be prepared in the form of a solution by mixing the extract of Cymbidium sieboldii with water together with a stabilizer or a buffer, and may be commercialized in a unit dosage form such as an ampule or a vial, and may be administered by subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.

[0060] The dosage of the pharmaceutical composition for alleviating irritable bowel syndrome containing the rhododendron extract of the present invention as an active ingredient should be prescribed by a physician depending on factors such as the patient's weight, age, and the specific nature and severity of the disease. However, the oral or parenteral dosage required for adult treatment may be in the range of 100 to 2,000 mg, preferably 100 to 1,000 mg, and more preferably 100 to 400 mg, administered orally once or twice daily. [Example]

[0061] Preferred examples are presented below to aid in understanding the present invention. However, the following examples are merely illustrative of the present invention, and it will be apparent to those skilled in the art that various changes and modifications are possible within the scope of the scope and technical idea of ​​the present invention. Naturally, such changes and modifications fall within the scope of the appended claims.

[0062] Example 1: Preparation of Goldfinch Extract 100g of rhododendron buds were dried and crushed, then added to 100mL of purified water and heated at 60℃ for 4 hours to extract and filter. After that, the extract was concentrated at 30℃ for 2 hours to produce rhododendron extract.

[0063] Then, maltodextrin was mixed as an excipient for powdering the extract, and the mixture was dried under reduced pressure at 40° C. for 14 hours to prepare 60 g of powdered diadem extract.

[0064] Experimental Example 1: Evaluation of Gastrointestinal Symptom Rating Scale (GSRS) Using the rhododendron extract prepared in Example 1, an experiment was carried out to determine the preventive or therapeutic efficacy for the symptoms of irritable bowel syndrome.

[0065] The specific experimental subjects, experimental methods, experimental items and experimental results are as follows:

[0066] 1-1. Experimental subjects - Adult men and women aged 19 and over - Patients with upper abdominal discomfort or persistent / recurrent pain who have been diagnosed with functional dyspepsia (Rome III criteria) and do not require immediate medical treatment - Subjects who have signed the written consent form for human application studies and are able to cooperate with visits, related tests, and questionnaires required during the research process. - Number of participants: 92 in total (test group: 46, control group: 46) - Number of participants for final data analysis: 73 in total (test group: 38, control group: 35)

[0067] 1-2. Experimental method The cataract extract prepared in Example 1 was prepared into tablets. The cataract extract was prepared into cataract extract tablets (300 mg / tablet) using a conventional method. The cataract extract content in the tablets was adjusted to 125 mg / tablet.

[0068] The test group was administered the above-mentioned rhododendron extract tablets twice a day, one tablet each time, for 8 weeks, and the dosage of the rhododendron extract was 250 mg / day.

[0069] The control group was administered one tablet containing only maltodextrin (300 mg / tablet) twice a day for eight weeks.

[0070] 1-3. Experimental results (1) Evaluation items After completing the experiment, the test group and the control group were given a questionnaire regarding the Gastrointestinal Symptom Rating Scale (GSRS).

[0071] Table 1 below categorizes the gastrointestinal and functional symptom scales.

[0072] [Table 1]

[0073] The questionnaire included seven items from the gastrointestinal function symptom scale in Table 1, including three items related to constipation syndrome, three items related to diarrhea syndrome, and an item related to borborygmi associated with irritable growth disorder. The seven items included borborygmi, which is abdominal noise; constipation symptoms of decreased passage of stools, hard stools, and a feeling of incomplete evacuation; and diarrhea symptoms of increased passage of stools, loose stools, and an urgent need for defecation.

[0074] (1) Evaluation method The degree of improvement in seven symptoms, including constipation, diarrhea, and borborygmi, was classified into four levels, and the strength of improvement in each symptom was evaluated for the test group and the control group. The results were analyzed using the Mann-Whitney U test, which is a statistical analysis method. Statistical analysis of the results before and after the intake of the cinnamon extract was performed using the Wilcoxon signed-rank test.

[0075] (2) Evaluation results Figure 1 is a graph showing the results of evaluating the degree of improvement in constipation and diarrhea symptoms in the test group administered with the rhododendron extract of Example 1 and the control group. Referring to Figure 1, it can be seen that the test group administered with the rhododendron extract of Example 1 (rhododendron extract tablets) showed a significant improvement in diarrhea symptoms compared to the control group (Placebo). In the figure, the test group is labeled "rhododendron" and the control group is labeled "Placebo."

[0076] FIG. 2 is a graph showing the results of evaluating the degree of improvement in minor symptoms related to constipation and diarrhea in the test group administered with the rhododendron extract of Example 1 and the control group.

[0077] FIG. 3 is a graph showing the results of evaluating the degree of improvement in borborygmus symptoms for the test group administered with the rhododendron extract of Example 1 and the control group.

[0078] In this regard, the detailed symptoms related to constipation and diarrhea include constipation symptoms such as decreased passage of stools, hard stools, and feeling of incomplete evacuation, and diarrhea symptoms such as increased passage of stools, loose stools, and urgent need for defecation.

[0079] Referring to Figure 2, it can be seen that the test group administered with the rhododendron extract of Example 1 (rhododendron extract tablets) showed significant improvement in diarrhea symptoms such as loose stools and urgent bowel movements compared to the control group (Placebo).

[0080] Referring to FIG. 3, it can be seen that the test group administered with the rhododendron extract of Example 1 (rhododendron extract tablets) showed a significant improvement in borborygmus symptoms compared to the control group (Placebo).

[0081] Table 2 below shows the detailed symptom evaluation results related to the constipation and diarrhea symptoms for the test group and the control group before administration of the Goldenrod extract tablets (Baseline, Day 0), 4 weeks (Day 28) and 8 weeks (Day 56) after administration.

[0082] [Table 2]

[0083] (X±SD)X=Mean. SD=Standard deviation. *p< 0.05, **p<0.01, ***p<0.001, ****p<0.0001 Comparisons with baseline (wilcoxon test for matched samples). +p<0.05, ++p<0.01Comparisons with placebo (Mann Whitney U test).

[0084] Referring to Table 2, it can be seen that the test group administered with the rhododendron extract of Example 1 showed significant improvement in diarrhea symptoms such as loose stools, urgent bowel movements, and borborygmus compared to the control group.

[0085] Furthermore, referring to Table 2, the test group administered with the rhododendron extract of Example 1 showed significant improvements in five of the seven items, namely, decreased bowel movements, incomplete evacuation sensation, loose stools, bowel urgency symptoms, and borborygmus, compared to before administration of the rhododendron extract. No significant improvement was observed in the control group.

[0086] These results show that the rhododendron extract of the present invention is effective in improving irritable bowel syndrome, and in particular, diarrheal symptoms including loose stools, urgent bowel movements and / or borborygmus symptoms are significantly improved, and that the rhododendron extract is particularly effective in improving irritable bowel syndrome accompanied by diarrhea.

[0087] Experimental Example 2 8-OHdG is a biomarker for measuring oxidative stress and is used as a biological indicator of cellular DNA damage, and has been reported to be associated with inflammatory diseases, particularly irritable bowel syndrome (IBS), a gastrointestinal disease (Kauppi J, Rasanen J, Sihvo E, Nieminen U, et al., Transl Oncel. 2016;9:336-339; Albayrak F, Uyanik MH, Dursun H, Albayrak Y, et al., South Med J. 2010;103:753-757). In other words, the lower the blood concentration of 8-OHdG, the more the symptoms of IBS improve.

[0088] Therefore, the test group and the control group of Experimental Example 1 were subjected to hematological analysis of the blood concentration of 8-OHdG, and the Mann-Whitney U test, which is a statistical analysis method, was used.

[0089] FIG. 4 is a graph showing the results of hematological analysis related to blood 8-OHdG concentration for the test group administered with the rhododendron extract of Example 1 and the control group.

[0090] Referring to FIG. 4, it can be seen that the test group administered with the rhododendron extract of Example 1 (purified rhododendron extract) had a significantly reduced blood 8-OHdG concentration compared to the control group (Placebo).

[0091] This indicates that the extract of the Goldenrod is effective in alleviating irritable bowel syndrome.

[0092] Although the present invention has been described above using limited examples and drawings, the present invention is not limited thereto, and it goes without saying that various modifications and variations can be made by a person having ordinary skill in the art to which the present invention pertains within the technical spirit of the present invention and the equivalent scope of the claims set forth below.

Claims

1. A functional food composition for alleviating irritable bowel syndrome, comprising an extract of Lonicera japonica as an active ingredient, The rhododendron extract is a rhododendron water extract extracted with water, The cypress extract is contained in an amount of 0.1 to 10 wt % based on the total weight of the food composition; the irritable bowel syndrome is irritable bowel syndrome accompanied by one or more symptoms selected from the group consisting of borborygmi and diarrhea, The functional food composition, wherein the diarrhea comprises one or more symptoms selected from the group consisting of increased bowel movements, loose stools, and bowel urgency.

2. The functional food composition according to claim 1, wherein the extract of Cyperus sieboldii is an organic solvent fraction of the extract of Cyperus sieboldii.

3. 3. The functional food composition according to claim 2, wherein the organic solvent is at least one selected from the group consisting of ethyl acetate, dichloromethane, chloroform, and butanol.

4. The functional food composition according to claim 1, wherein the food composition further comprises an excipient and / or an additive.

5. The functional food composition according to claim 1, wherein the food composition is formulated in a form selected from the group consisting of tablets, capsules, powders, liquid phases, granules, rings, flakes, pastes, syrups, gels, jellies, caramels, gummies, and bars.

6. A pharmaceutical composition for alleviating irritable bowel syndrome, comprising an extract of Cymbidium ginseng as an active ingredient, The rhododendron extract is a rhododendron water extract extracted with water, the irritable bowel syndrome is irritable bowel syndrome accompanied by one or more symptoms selected from the group consisting of borborygmi and diarrhea, The diarrhea comprises one or more symptoms selected from the group consisting of increased bowel movements, loose stools, and bowel urgency.

7. The pharmaceutical composition according to claim 6, further comprising an excipient and / or additive.

8. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is formulated into one or more oral administration forms selected from the group consisting of tablets, pills, hard / soft capsules, liquids, emulsions, syrups, and granules.

9. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is formulated into one or more parenteral administration forms selected from the group consisting of subcutaneous injections, intravenous injections, intramuscular injections, intrathoracic injections, and suppositories.

10. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is administered in the range of 100 to 2000 mg once or twice a day.

Images